Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Common Stock (Tables)

Common Stock (Tables)

9 Months Ended

Sep. 30, 2012

Components of stock-based compensation expense

The following table summarizes the stock-based compensation expense from awards, including stock options and restricted Common Stock awards to employees and non-employees, compensation expense for the ESPP and warrants to non-employees for the nine months ended September 30, 2012 and 2011, and from the period June 28, 2006 (date of inception) to date.


	For the nine months ended September 30,				Period from June 28, 2006 (date of inception) to September 30,
($ in thousands)	2012		2011		2012
Employee awards	$	1,336	$	359	$	2,071
Non-employee awards		412		192		3,225
Non-employee warrants		425		231		752

Total stock-based compensation expense	$	2,173	$	782	$	6,048

Summary of stock option activity

The following table summarizes stock option activity:


	Outstanding Options						Weighted Average Remaining Contractual Life (in years)
($ in thousands except per share amounts)	Number of Shares		Weighted Average Exercise Price		Total Weighted Average Intrinsic Value		Weighted Average Remaining Contractual Life (in years)
At December 31, 2011		1,814,070	$	2.17	$	7,852		9.2
Options granted		620,000		6.86
Options exercised		—
Options cancelled		25,000

At September 30, 2012		2,409,070	$	3.28	$	4,573		8.7

Options vested and expected to vest		2,409,070	$	3.28	$	4,573		8.7
Options vested and exercisable		578,023	$	1.96	$	1,873		8.4